| Dr James Francesconi, MD | |
|
109 River Oaks Dr Ste 150, Southlake, TX 76092-6764 | |
| (817) 379-9922 | |
| (817) 379-9998 |
| Full Name | Dr James Francesconi |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 12 Years |
| Location | 109 River Oaks Dr Ste 150, Southlake, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326209800 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | P3624 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Center For Neurology And Neurophysiology, P.a. | 3779764071 | 2 |
| Attigo Infusion Inc | 5597190645 | 47 |
News Archive
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
The United States Departments of Health and Human Services, Labor and the Treasury announced yesterday a new internal claims and appeals and external review process for group health plans under the Patient Protection and Affordable Care Act.
› Verified 7 days ago
| Entity Name | The Center For Neurology And Neurophysiology, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194035717 PECOS PAC ID: 3779764071 Enrollment ID: O20110218001001 |
News Archive
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
The United States Departments of Health and Human Services, Labor and the Treasury announced yesterday a new internal claims and appeals and external review process for group health plans under the Patient Protection and Affordable Care Act.
› Verified 7 days ago
| Entity Name | Attigo Infusion Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891339644 PECOS PAC ID: 5597190645 Enrollment ID: O20200117000376 |
News Archive
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
The United States Departments of Health and Human Services, Labor and the Treasury announced yesterday a new internal claims and appeals and external review process for group health plans under the Patient Protection and Affordable Care Act.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Francesconi, MD 7000 Parkwood Blvd, Ste F100, Frisco, TX 75034-7407 Ph: (214) 494-4424 | Dr James Francesconi, MD 109 River Oaks Dr Ste 150, Southlake, TX 76092-6764 Ph: (817) 379-9922 |
News Archive
This post in USAID's "IMPACTblog" examines the agency's work with women suffering from obstetric fistula in Guinea, where "[t]he average ... woman will have six children during her lifetime" and "due to the lack of obstetric care," many develop the "painful injury that is especially traumatic due to the stigma associated with it."
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
The United States Departments of Health and Human Services, Labor and the Treasury announced yesterday a new internal claims and appeals and external review process for group health plans under the Patient Protection and Affordable Care Act.
› Verified 7 days ago
Dr. Mahta Ostadian, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 541 Silicon Dr Ste 102, Southlake, TX 76092 Phone: 817-539-6819 Fax: 817-539-6870 | |
Dr. Nishant Rajesh Patel, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 541 Silicon Dr Ste 102, Southlake, TX 76092 Phone: 817-539-6819 | |
Dr. Joe Boyd Bates, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1500 Corporate Cir Ste 7, Southlake, TX 76092 Phone: 417-761-5006 Fax: 417-761-5065 | |
Viktoria Zatkalik, NP-C Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 109 River Oaks Dr Ste 150, Southlake, TX 76092 Phone: 817-379-9922 Fax: 817-379-9998 | |
Rodolfo Molina, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2485 E Southlake Blvd Ste 100, Southlake, TX 76092 Phone: 817-873-0595 | |
Mrs. Laura Marcela Fredes, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 536 Silicon Dr Ste 102, Southlake, TX 76092 Phone: 817-203-4179 Fax: 817-259-2793 |